1 Methyl arachidonyl fluorophosphonate (MAFP), an inhibitor of phospholipase A(2) (PLA(2)), has been widely used to assess the roles of PLA(2) in various cell functions. Here, we report on a novel action of this compound at concentrations similar to those used for PLA(2) inhibition. 2 The murine macrophage J774 released a large amount of prostaglandin E-2 (PGE(2) by MAFP (1-30 mu M), which was abolished by indomethacin and NS-398 but not by valeryl salicylate, and results from increased cyclo-oxygenase-2 (COX-2) protein levels and gene expression. 3 This PGE(2) release was blocked by inhibitors of tyrosine kinase (genistein), protein kinase C (PKC) (Ro 31-8220, Go 6976 or LY 379196), mitogen-activated protein kinase kinase (MEK) (PD 098059) or p38 mitogen-activated protein kinase (MAPK) (SB 203580). 4 Consistent with these results, MAFP caused membrane translocation of PKC beta I and beta II isoforms and activated extracellular signal-regulated kinase (ERK) and p38 MAPK. 5 In accordance with these effects of MAFP, PKC activator phorbol 12-myristate 13-acetate (PMA) increased PGE(2) release and caused activation of PKC beta, ERKs and p38 MAPK. 6 This is the first report that the PLA(2) inhibitor, MAFP, can induce COX-2 gene expression and PGE(2) synthesis via the PKC-, ERK- and p38 MAPK-dependent pathways. Thus, the use of MAFP as a PLA(2) inhibitor should be treated with caution.